Isamida T, Tanaka T, Omata Y, Yamauchi K, Shimazaki K, Saito A
Department of Veterinary Physiology, Obihiro University of Agriculture and Veterinary Medicine, Hokkaido, Japan.
J Vet Med Sci. 1998 Feb;60(2):241-4. doi: 10.1292/jvms.60.241.
The protective effect of lactoferricin against Toxoplasma gondii infection was examined in experimental murine toxoplasmosis. All mice orally administered 5.0 mg of lactoferricin, and challenged with cysts of T. gondii at a dose of LD90 survived until the end of experiment (35 days post challenge). Intraperitoneal administration of 0.1 mg of lactoferricin also prevented death in 100% of treated mice challenged with T. gondii cysts. In contrast, 80% of untreated mice died of acute toxoplasmosis within 14 days post challenge. In the mice treated perorally with lactoferricin, the number of cysts in the brain was significantly lower than that in untreated mice. Levels of interferon-r in the serum of infected mice treated perorally with lactoferricin showed a tendency to lower than those in the infected mice without treatment. These results demonstrate that oral administration of lactoferricin induces resistance to T. gondii infection in mice.
在实验性小鼠弓形虫病中检测了乳铁蛋白对弓形虫感染的保护作用。所有口服给予5.0毫克乳铁蛋白并以LD90剂量的弓形虫囊肿进行攻击的小鼠存活至实验结束（攻击后35天）。腹腔注射0.1毫克乳铁蛋白也可使100%接受弓形虫囊肿攻击的治疗小鼠免于死亡。相比之下，80%未治疗的小鼠在攻击后14天内死于急性弓形虫病。在经口用乳铁蛋白治疗的小鼠中，脑中囊肿数量明显低于未治疗小鼠。经口用乳铁蛋白治疗的感染小鼠血清中的干扰素-γ水平有低于未治疗感染小鼠的趋势。这些结果表明口服乳铁蛋白可诱导小鼠对弓形虫感染产生抗性。
